EATRIS to present at the European Association of Nuclea Medicine’s 27th Annual EANM Congress in Gothenburg, Sweden in October 2014.
The European Association of Nuclear Medicine (EANM) is the umbrella organisation of nuclear medicine in Europe and represents the sector towards the European Institutions. Within this role, the EANM aims at advancing science and education in nuclear medicine for the benefit of public health as well as at promoting and co-ordinating, throughout Europe and beyond, discussion and exchange of ideas and results relating to the diagnosis, treatment, research and prevention of diseases through the use of unsealed radioactive substances and the properties of stable nuclides in medicine. The goal of the EANM is thus to provide a suitable medium for the dissemination and discussion of the latest results in the field of nuclear medicine and related subjects.
For further information about EANM please visit www.eanm.org.
Despite advances on research at the molecular level with enhanced understanding of the the underlying mechanism of diseases researchers continue to struggle with the process of advancing research findings towards healthcare products in development. In recognition of this, EATRIS (www.eatris.eu) – European Advanced Translational Research InfraStructure in Medicine was founded in 2008 and entered operations in 2013 after being awarded permanent ERIC (European Research Infrastructure Consortium) legal status, a sign of the commitment of the 8 European countries participating in the initiative. EATRIS is a distributed infrastructure comprising over 70 non-profit and academic translational research institutions, collaborating to overcome bottlenecks in the development of drugs and diagnostics.
At the EANM’14 EATRIS will present the infrastructure that encompasses the complete translational pipeline up to clinical proof-of-concept, offering access to valuable infrastructure such as GMP manufacturing, high-end (molecular) imaging facilities, regulatory and clinical expertise and patient cohorts. EATRIS shares the goals of EARL-EANM to improve and advance scientific initiatives as well as clinical research projects. Together with EARL-EANM, EATRIS will develop strategies towards harmonisation and standardisation of (multimodal) PET imaging to improve the quality and speed of transnational access to multicentre clinical trial activities, involving (molecular) imaging to support innovative first in man trials involving PK/PD and mode of action studies as a distinguished feature of the infrastructure.
For further information about the congress please visit http://eanm14.eanm.org/.
